Anti-Cancer Drug Design Targeting Human Topoisomerase I

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 2R44CA079439-02
Amount: $748,938.00
Phase: Phase II
Program: SBIR
Awards Year: 2001
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 () -
Business Contact
Phone: (206) 780-8535
Research Institution
DESCRIPTION (provided by applicant): Human topoisomerase I (topo I) is the sole intracellular target of camptothecin (CPT) and other "topo I poisons," some of which are among the most promising anticancer drugs ever identified. Emerald BioStructures, Inc. has successfully completed a Phase I SBIR research program that sought to elucidate the X-ray crystal structure of human topo I in complex with one or another CPT-analogue. We now seek Phase 2 SBIR funds to conduct an integrated structure-based drug design cycle using our 2.0 angstrom structural information of Topotecan bound to the human topo I-DNA covalent complex. We will employ standard computational methods to formulate a three-dimensional quantitative structure-activity relationship (3D-QSAR) model for the camptothecin-type compounds. The 3D-QSAR model will be validated and extended with X-ray crystal structures of additional camptothecin analogues. The Available Chemicals Database and the World Drug Index will be computationally interrogated for ligands that fit into the Topotecan binding pocket of the topo I-DNA binding site. The 3D-QSAR information will be combined with the predicted ligand binding information and chemical intuition to design completely novel camptothecin analogues that have enhanced formulative properties (complete E-ring stability, efficient liposome encapsulation, facile conjugation to polyethylene glycol). The novel camptothecin analogues will be synthesized, purified, and tested for their inhibitory effects on topo I activity, their affinity for the covalent complex using immobilized topo I-DNA covalent complexes, and their cytotoxicity to human tumor cell lines. The most promising compounds will be examined for their efficacy in stopping human tumor growth in the mouse xenotransplant model. PROPOSED COMMERCIAL APPLICATION: Not available

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government